Cargando…

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients

BACKGROUND: Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). PegIFN/ribavirin has increased rate of sustained virological res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akram, Madiha, Idrees, Muhammad, Zafar, Shamail, Hussain, Abrar, Butt, Sadia, Afzal, Samia, Rehman, Irshad-ur, Liaqat, Ali, Saleem, Sana, Ali, Muhammad, Butt, Azeem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113307/ https://www.ncbi.nlm.nih.gov/pubmed/21575275 http://dx.doi.org/10.1186/1743-422X-8-234

Ejemplares similares

Envelope 2 protein phosphorylation sites S75 & 277 of hepatitis C virus genotype 1a and interferon resistance: A sequence alignment approach
por: Afzal, Samia, et al.
Publicado: (2011)

Characterization of Hepatitis C Virus genotype 3a Hypervariable region 1 in patients achieved rapid virological response to alpha interferon and Ribavirin Combination therapy
por: Akram, Madiha, et al.
Publicado: (2011)

Positional effect of phosphorylation sites 266 and 267 in the cytoplasmic domain of the E2 protein of hepatitis C virus 3a genotype: Interferon Resistance analysis via Sequence Alignment
por: Rafique, Shazia, et al.
Publicado: (2011)

Hepatitis B virus in Pakistan: A systematic review of prevalence, risk factors, awareness status and genotypes
por: Ali, Muhammad, et al.
Publicado: (2011)

Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients
por: Afzal, Samia, et al.
Publicado: (2010)

An overview of treatment response rates to various anti-viral drugs in Pakistani Hepatitis B Virus infected patients
por: Ali, Liaqat, et al.
Publicado: (2011)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Establishment of stable Huh-7 cell lines expressing various hepatitis C virus genotype 3a protein: an in-vitro testing system for novel anti-HCV drugs
por: Butt, Sadia, et al.
Publicado: (2011)

Transcriptional Analysis of TP53 Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, Pegylated Interferon, and Ribavirin
por: Chudhary, Hafiza Rida Farooq, et al.
Publicado: (2023)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Hepatitis C virus genotype 3a with phylogenetically distinct origin is circulating in Pakistan
por: Rehman, Irshad-ur, et al.
Publicado: (2011)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy
por: Kashif, Muhammad, et al.
Publicado: (2015)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Hepatitis Associated Aplastic Anemia: A review
por: Rauff, Bisma, et al.
Publicado: (2011)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
por: Lee, Tae-Hee, et al.
Publicado: (2014)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C
por: Heidari, Mehdi, et al.
Publicado: (2014)

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
por: Keshvari, Maryam, et al.
Publicado: (2016)

Effect of Functional Interleukin-10 Polymorphism on Pegylated Interferon-α Plus Ribavirin Therapy Response in Chronic Hepatitis C Virus Patients Infected With 3a Genotype in Pakistani Population
por: Afzal, Muhammad Sohail, et al.
Publicado: (2013)

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
por: Asselah, Tarik, et al.
Publicado: (2010)

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
por: Martins, Elson Vidal, et al.
Publicado: (2009)

Expectoration of Large Bronchial Casts Secondary to the Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin
por: de Araújo, Evaldo Stanislau Affonso, et al.
Publicado: (2010)

Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
por: Alhamlan, Fatimah S, et al.
Publicado: (2014)

Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2014)

Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy
por: Turker, Kamuran, et al.
Publicado: (2015)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
por: Rashed, Yasser K., et al.
Publicado: (2020)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015)

Large Intestine Histopathology of Pegylated-Interferon-Alpha Plus Ribavirin Treated Chronic Hepatitis C Patients
por: Pantazis, Konstantinos D., et al.
Publicado: (2008)

Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
por: Kim, Hong Joo, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_mchunirmvue9q5p271pspsqdpt